Autoimmune And Rheumatic Diseases

The recent acquisition of Horizon Therapeutics by Amgen continues a trend in medical finance that may have implications for both rheumatologists and their patients.

The EULAR Congress of Rheumatology is set to return this spring as an in-person, onsite-only event, with no live remote options, for the first time since the beginning of the COVID-19 pandemic.

I have been told that I wanted to be a physician since I was a little kid, likely influenced by my maternal grandfather, Bernard Aschner, MD. He was a gynecologic surgeon and physiologist trained in Vienna and Berlin, who showed that the pituitary gland controls growth and sexual development by successfully performing transsphenoidal hypophysectomies in pups and comparing them to controls from the same litter. He later taught the surgical technique to the neurosurgeon Harvey Cushing, MD.

Patients with systemic autoimmune rheumatic diseases who are fully vaccinated against COVID-19 are less likely to experience long COVID symptoms, compared with unvaccinated patients, according to data.

Family history of autoimmune disease is a risk factor for developing of juvenile idiopathic arthritis, although it does not impact disease severity or course, according to data published in Pediatric Rheumatology.

Patients with autoimmune inflammatory rheumatic diseases should be screened for tuberculosis, hepatitis B and other infections before starting disease-modifying antirheumatic drugs, according to new guidelines published by EULAR.

Searching for a future discipline to pursue during my time in medical school at the University of Rochester in New York, I grappled with family medicine, psychiatry and neurology.

Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release.

Antinuclear antibody prevalence in the United States has grown from 11% during the period of 1988 to 1991, to 16.1% during 2011 to 2012, according to data published in Arthritis & Rheumatology.

PHILADELPHIA — Patients with rheumatic diseases and previous malignancy do not demonstrate a higher cancer risk with TNF inhibitors vs. other biologic and targeted synthetic DMARDs, according to data presented at ACR Convergence 2022.